In the last trading session, 1.4 million shares of the Fate Therapeutics Inc (NASDAQ:FATE) were traded, and its beta was 2.26. Most recently the company’s share price was $1.22, and it changed around $0.06 or 5.17% from the last close, which brings the market valuation of the company to $139.85M. FATE currently trades at a discount to its 52-week high of $5.92, offering almost -385.25% off that amount. The share price’s 52-week low was $0.66, which indicates that the current value has risen by an impressive 45.9% since then. We note from Fate Therapeutics Inc’s average daily trading volume that its 10-day average is 1.69 million shares, with the 3-month average coming to 2.21 million.
Fate Therapeutics Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.42. If we narrow it down even further, the data shows that 0 out of 14 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 9 recommended FATE as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight.
Fate Therapeutics Inc (NASDAQ:FATE) trade information
Instantly FATE has showed a green trend with a performance of 5.17% at the end of last trading. The rise to weekly highs of 1.3000 on recent trading dayincreased the stock’s daily price by 6.15%. On the other hand, Fate Therapeutics Inc (NASDAQ:FATE) is -4.69% down in the 30-day period. We can see from the shorts that 13.34 million shares have been sold at a short interest cover period of 5.44 day(s).
The consensus price target as assigned by Wall Street analysts is $3, which translates to bulls needing to increase their stock price by 59.33% from its current value. Analyst projections state that FATE is forecast to be at a low of $3 and a high of $3.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -2.63%. Fate Therapeutics Inc earnings are expected to increase by 20.40% in 2025, but the outlook is positive 12.42% per year for the next five years.
FATE Dividends
Fate Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-May-12.
Fate Therapeutics Inc (NASDAQ:FATE)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.74% of Fate Therapeutics Inc shares, and 94.28% of them are in the hands of institutional investors. The stock currently has a share float of 95.95%. Fate Therapeutics Inc stock is held by 184.0 institutions, with REDMILE GROUP, LLC being the largest institutional investor. By 2024-06-30, it held 11.2107% of the shares, which is about 13.17 million shares worth $43.19 million.
VANGUARD GROUP INC, with 8.998% or 10.57 million shares worth $34.67 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF were the top two Mutual Funds as of Dec 31, 2024 . The former held 3.05 shares worth $3.72 million, making up 2.66% of all outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held roughly 2.62 shares worth around $3.2 million, which represents about 2.29% of the total shares outstanding.
